These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 37633912)

  • 1. Remibrutinib (LOU064) inhibits neuroinflammation driven by B cells and myeloid cells in preclinical models of multiple sclerosis.
    Nuesslein-Hildesheim B; Ferrero E; Schmid C; Huck C; Smith P; Tisserand S; Rubert J; Bornancin F; Eichlisberger D; Cenni B
    J Neuroinflammation; 2023 Aug; 20(1):194. PubMed ID: 37633912
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bruton's tyrosine kinase inhibition reduces disease severity in a model of secondary progressive autoimmune demyelination.
    Evonuk KS; Wang S; Mattie J; Cracchiolo CJ; Mager R; Ferenčić Ž; Sprague E; Carrier B; Schofield K; Martinez E; Stewart Z; Petrosino T; Johnson GA; Yusuf I; Plaisted W; Naiman Z; Delp T; Carter L; Marušić S
    Acta Neuropathol Commun; 2023 Jul; 11(1):115. PubMed ID: 37438842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Remibrutinib (LOU064): A selective potent oral BTK inhibitor with promising clinical safety and pharmacodynamics in a randomized phase I trial.
    Kaul M; End P; Cabanski M; Schuhler C; Jakab A; Kistowska M; Kinhikar A; Maiolica A; Sinn A; Fuhr R; Cenni B
    Clin Transl Sci; 2021 Sep; 14(5):1756-1768. PubMed ID: 33834628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MOG autoantibodies trigger a tightly-controlled FcR and BTK-driven microglia proliferative response.
    Pellerin K; Rubino SJ; Burns JC; Smith BA; McCarl CA; Zhu J; Jandreski L; Cullen P; Carlile TM; Li A; Rebollar JV; Sybulski J; Reynolds TL; Zhang B; Basile R; Tang H; Harp CP; Pellerin A; Silbereis J; Franchimont N; Cahir-McFarland E; Ransohoff RM; Cameron TO; Mingueneau M
    Brain; 2021 Sep; 144(8):2361-2374. PubMed ID: 34145876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of the Btk-Inhibitors Remibrutinib (LOU064) and Rilzabrutinib (PRN1008) With Varying Btk Selectivity Over Tec on Platelet Aggregation and
    Duan R; Goldmann L; Brandl R; Spannagl M; Weber C; Siess W; von Hundelshausen P
    Front Cardiovasc Med; 2021; 8():749022. PubMed ID: 34631841
    [No Abstract]   [Full Text] [Related]  

  • 6. Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
    Angst D; Gessier F; Janser P; Vulpetti A; Wälchli R; Beerli C; Littlewood-Evans A; Dawson J; Nuesslein-Hildesheim B; Wieczorek G; Gutmann S; Scheufler C; Hinniger A; Zimmerlin A; Funhoff EG; Pulz R; Cenni B
    J Med Chem; 2020 May; 63(10):5102-5118. PubMed ID: 32083858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual roles of the adenosine A2a receptor in autoimmune neuroinflammation.
    Ingwersen J; Wingerath B; Graf J; Lepka K; Hofrichter M; Schröter F; Wedekind F; Bauer A; Schrader J; Hartung HP; Prozorovski T; Aktas O
    J Neuroinflammation; 2016 Feb; 13():48. PubMed ID: 26920550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dopaminergic stimulation leads B-cell infiltration into the central nervous system upon autoimmunity.
    Prado C; Osorio-Barrios F; Falcón P; Espinoza A; Saez JJ; Yuseff MI; Pacheco R
    J Neuroinflammation; 2021 Dec; 18(1):292. PubMed ID: 34920747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of Bruton's tyrosine kinase interferes with pathogenic B-cell development in inflammatory CNS demyelinating disease.
    Torke S; Pretzsch R; Häusler D; Haselmayer P; Grenningloh R; Boschert U; Brück W; Weber MS
    Acta Neuropathol; 2020 Oct; 140(4):535-548. PubMed ID: 32761407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the RNA-Binding Protein HuR Alleviates Neuroinflammation in Experimental Autoimmune Encephalomyelitis: Potential Therapy for Multiple Sclerosis.
    Borgonetti V; Sanna MD; Lucarini L; Galeotti N
    Neurotherapeutics; 2021 Jan; 18(1):412-429. PubMed ID: 33200288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lack of junctional adhesion molecule (JAM)-B ameliorates experimental autoimmune encephalomyelitis.
    Tietz S; Périnat T; Greene G; Enzmann G; Deutsch U; Adams R; Imhof B; Aurrand-Lions M; Engelhardt B
    Brain Behav Immun; 2018 Oct; 73():3-20. PubMed ID: 29920328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BTK inhibition limits microglia-perpetuated CNS inflammation and promotes myelin repair.
    Geladaris A; Torke S; Saberi D; Alankus YB; Streit F; Zechel S; Stadelmann-Nessler C; Fischer A; Boschert U; Häusler D; Weber MS
    Acta Neuropathol; 2024 Apr; 147(1):75. PubMed ID: 38656399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subcutaneous anti-CD20 antibody treatment delays gray matter atrophy in human myelin oligodendrocyte glycoprotein-induced EAE mice.
    Pol S; Liang S; Schweser F; Dhanraj R; Schubart A; Preda M; Sveinsson M; Ramasamy DP; Dwyer MG; Weckbecker G; Zivadinov R
    Exp Neurol; 2021 Jan; 335():113488. PubMed ID: 32991933
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Translocator Protein Ligand PIGA1138 Reduces Disease Symptoms and Severity in Experimental Autoimmune Encephalomyelitis Model of Primary Progressive Multiple Sclerosis.
    Tremolanti C; Cavallini C; Meyer L; Klein C; Da Pozzo E; Costa B; Germelli L; Taliani S; Patte-Mensah C; Mensah-Nyagan AG
    Mol Neurobiol; 2022 Mar; 59(3):1744-1765. PubMed ID: 35018577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mannan-MOG35-55 Reverses Experimental Autoimmune Encephalomyelitis, Inducing a Peripheral Type 2 Myeloid Response, Reducing CNS Inflammation, and Preserving Axons in Spinal Cord Lesions.
    Dagkonaki A; Avloniti M; Evangelidou M; Papazian I; Kanistras I; Tseveleki V; Lampros F; Tselios T; Jensen LT; Möbius W; Ruhwedel T; Androutsou ME; Matsoukas J; Anagnostouli M; Lassmann H; Probert L
    Front Immunol; 2020; 11():575451. PubMed ID: 33329540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic effect of the total saponin from Panax Japonicus on experimental autoimmune encephalomyelitis by attenuating inflammation and regulating gut microbiota in mice.
    Wang J; He L; Wang S; Zhao H; Chen J; Dong Y; Yasen S; Wang L; Zou H
    J Ethnopharmacol; 2023 Oct; 315():116681. PubMed ID: 37230280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The relation between BTK expression and iron accumulation of myeloid cells in multiple sclerosis.
    Steinmaurer A; Riedl C; König T; Testa G; Köck U; Bauer J; Lassmann H; Höftberger R; Berger T; Wimmer I; Hametner S
    Brain Pathol; 2024 Sep; 34(5):e13240. PubMed ID: 38254312
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IC100: a novel anti-ASC monoclonal antibody improves functional outcomes in an animal model of multiple sclerosis.
    Desu HL; Plastini M; Illiano P; Bramlett HM; Dietrich WD; de Rivero Vaccari JP; Brambilla R; Keane RW
    J Neuroinflammation; 2020 May; 17(1):143. PubMed ID: 32366256
    [TBL] [Abstract][Full Text] [Related]  

  • 19. B-cell activation influences T-cell polarization and outcome of anti-CD20 B-cell depletion in central nervous system autoimmunity.
    Weber MS; Prod'homme T; Patarroyo JC; Molnarfi N; Karnezis T; Lehmann-Horn K; Danilenko DM; Eastham-Anderson J; Slavin AJ; Linington C; Bernard CC; Martin F; Zamvil SS
    Ann Neurol; 2010 Sep; 68(3):369-83. PubMed ID: 20641064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paricalcitol improves experimental autoimmune encephalomyelitis (EAE) by suppressing inflammation via NF-κB signaling.
    Zhang D; Qiao L; Fu T
    Biomed Pharmacother; 2020 May; 125():109528. PubMed ID: 32106388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.